<scp>DNL</scp>104, a Centrally Penetrant <scp>RIPK</scp>1 Inhibitor, Inhibits <scp>RIP</scp>1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy VolunteersHendrika W. Grievink, Geert Jan Groeneveld|Clinical Pharmacology & Therapeutics|2019Cited by 77